Hospital Universitario de la Princesa -ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2021

  1. Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: An observational study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 453-455

2020

  1. "There is something you must see": breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective

    Clinical and experimental rheumatology, Vol. 38, Núm. 1, pp. 82-87

  2. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

    Autoimmunity Reviews, Vol. 19, Núm. 1

  3. Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: A protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)

    Trials, Vol. 21, Núm. 1

  4. Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 1, pp. 166-171

2019

  1. Lamin A/C deficiency in CD4+ T-cells enhances regulatory T-cells and prevents inflammatory bowel disease

    Journal of Pathology, Vol. 249, Núm. 4, pp. 509-522

2018

  1. Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism

    Annals of the Rheumatic Diseases, Vol. 77, Núm. 5, pp. 752-759

2017

  1. Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: Time for a new approach?

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 5, pp. 816-822

2015

  1. CXCL12 regulates through JAK1 and JAK2 formation of productive immunological synapses

    Journal of Immunology, Vol. 194, Núm. 11, pp. 5509-5519

  2. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin a-dependent pro-inflammatory profile

    Journal of Pathology, Vol. 235, Núm. 3, pp. 515-526

2014

  1. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction

    Journal of Molecular Neuroscience, Vol. 52, Núm. 1, pp. 10-17

2013

  1. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts

    Rheumatology (United Kingdom), Vol. 52, Núm. 12, pp. 2177-2186

  2. Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: Immunomodulation by vasoactive intestinal peptide

    NeuroImmunoModulation, Vol. 20, Núm. 5, pp. 274-284

2012

  1. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features

    Arthritis Research and Therapy, Vol. 14, Núm. 2

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

  2. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, Eotaxin-3, and MHC2TA

    Journal of Rheumatology, Vol. 36, Núm. 8, pp. 1590-1595

  3. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors

    Arthritis and Rheumatism, Vol. 60, Núm. 9, pp. 2558-2564